Dendritic cell vaccination, immune regulation and clinical outcomes in ovarian cancer
Clinical optimism for dendritic cell vaccination against ovarian cancer has been tempered by the knowledge that tumors avail themselves of multiple mechanisms of immune evasion, thus blunting the efficacy of therapeutic vaccination. Mechanisms of immune suppression include infiltration by regulatory...
Main Authors: | Hannah E Goyne, Martin J Cannon |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2013-11-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fimmu.2013.00382/full |
Similar Items
-
The aryl hydrocarbon receptor meets immunology: friend or foe? A little of both
by: Walker eJulliard, et al.
Published: (2014-10-01) -
IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation
by: Adaobi Amobi-McCloud, et al.
Published: (2021-04-01) -
Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages
by: Martin J. Cannon, et al.
Published: (2015-05-01) -
From Suppressor T Cells to Regulatory T Cells: How the Journey that Began with the Discovery of the Toxic Effects of TCDD Led to Better Understanding of the Role of AhR in Immunoregulation
by: Narendra Prasad Singh, et al.
Published: (2020-10-01) -
IDO2 in immunomodulation and autoimmunity
by: George ePrendergast, et al.
Published: (2014-11-01)